Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions

2015; Oxford University Press; Volume: 213; Issue: 8 Linguagem: Inglês

10.1093/infdis/jiv564

ISSN

1537-6613

Autores

Evguenia S. Svarovskaia, Edward Gane, Hadas Dvory‐Sobol, Ross Martin, Brian Doehle, Charlotte Hedskog, Ira M. Jacobson, David R. Nelson, Eric Lawitz, Diana M. Brainard, John G. McHutchison, Michael D. Miller, Hongmei Mo,

Tópico(s)

HIV/AIDS drug development and treatment

Resumo

Background. Sofosbuvir (SOF) exhibits a high barrier to resistance, with no S282T NS5B substitution or phenotypic resistance detected in phase 3 registration studies.

Referência(s)